Peter Oppelt, MD - Washington ...

Dr. Peter Oppelt, M.D.

Claim this profile

Washington University School of Medicine

Studies Squamous Cell Carcinoma
Studies Head and Neck Squamous Cell Carcinoma
26 reported clinical trials
53 drugs studied

Area of expertise

1

Squamous Cell Carcinoma

Peter Oppelt, M.D. has run 9 trials for Squamous Cell Carcinoma. Some of their research focus areas include:

Stage IV
p16 positive
p16 negative
2

Head And Neck Squamous Cell Carcinoma

Peter Oppelt, M.D. has run 7 trials for Head and Neck Squamous Cell Carcinoma. Some of their research focus areas include:

p16 positive
Stage IV
p16 negative

Affiliated Hospitals

Image of trial facility.

Washington University School Of Medicine

Image of trial facility.

Washington University School Of Medicine

Clinical Trials Peter Oppelt, M.D. is currently running

Image of trial facility.

Registry

for Peripheral Nerve Sheath Tumor

First, the investigators plan to use a retrospective analysis to determine the clinical landscape of neurofibromatosis (NF)1-associated malignant peripheral nerve sheath tumor (MPNST) and precursor lesions (e.g., atypical or nodular plexiform neurofibromas). A worldwide database will be established, collecting, in a standardized manner, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from centers worldwide with expertise in these NF1-related cancers. Although retrospective in nature, the resulting data from this registry may reveal previously unanticipated patterns, similar to the INFACT effort outcome. This registry would then allow the acquisition of data associated with MPNST biospecimens collected under associated banks (frozen or paraffin-embedded, germline (or normal tissue DNA) samples, and any previously somatic whole-exome or whole-genome sequencing data for aggregate analyses). Second, the investigators plan to co-register patients to institutional banks in order to prospectively collect MPNST samples for analysis. These patients will be consented in order to collect the above information and for banking of tumor tissue and future studies that include genomic characterization of the tumors.

Recruiting

1 award

N/A

1 criteria

Image of trial facility.

Ramucirumab + Pembrolizumab

for Head and Neck Cancer

This is a phase 2 study investigating the efficacy of ramucirumab in combination with pembrolizumab compared to pembrolizumab monotherapy. Ramucirumab is a VEGFR-2 inhibitor believed to potentially enhance the efficacy of PD-1 inhibitors such as pembrolizumab.

Recruiting

1 award

Phase 2

17 criteria

More about Peter Oppelt, M.D.

Clinical Trial Related

4 years of experience running clinical trials · Led 26 trials as a Principal Investigator · 8 Active Clinical Trials

Treatments Peter Oppelt, M.D. has experience with

  • Pembrolizumab
  • Nivolumab
  • Atezolizumab
  • Ramucirumab
  • Carboplatin
  • Cisplatin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Peter Oppelt, M.D. specialize in?

Is Peter Oppelt, M.D. currently recruiting for clinical trials?

Are there any treatments that Peter Oppelt, M.D. has studied deeply?

What is the best way to schedule an appointment with Peter Oppelt, M.D.?

What is the office address of Peter Oppelt, M.D.?

Is there any support for travel costs?